Ramucirumab
Summary
Hazard - P - B - T - Risk Exempt
Assessment report
Assessment report for Cyramza (ramucirumab), 17 December 2015, EMA/CHMP/69143/2016.
"No ERA was submitted."
Fass environmental information
Fass environmental information for Cyramza from Lilly (downloaded 2019-09-04).
Detailed information
According to the European Medicines Agency guideline on environmental risk assessments for pharmaceuticals (EMA/CHMP/SWP/4447/00), vitamins, electrolytes, amino acids, peptides, proteins, carbohydrates, lipids proteins, vaccines and herbal medicinal products are exempted because they are unlikely to result in significant risk to the environment.
References
- European Medicines Agency. European public assessment reports (EPAR). Cyramza (ramucirumab), 17 December 2015, EMA/CHMP/69143/2016.
- Fass för vårdpersonal.
- European Medicines Agency, EMA: Committee for Medicinal Products for Human Use (CHMP). Guideline on the Environmental Risk Assessment of Medicinal Products for Human Use. 1 June 2006.
Author: Health and Medical Care Administration, Region Stockholm